SCHEMBL2803950

SCHEMBL2803950

COc1ccc(-c2ccc(-c3nc(-c4ccc(C(=O)O)c(F)c4)no3)cc2C)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 9/20 0.56
S1PR3 Q99500 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
TP53 P04637 2/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
RARA P10276 4/20 0.53
RARB P10826 4/20 0.53
RARG P13631 4/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
HTT P42858 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2772526 0.93 S1PR1 (0.56) S1PR1S1PR3SMN1; SMN2TP53NFKB1
SCHEMBL2772630 0.93 TP53 (0.53) S1PR1S1PR3SMN1; SMN2TP53NFKB1
SCHEMBL2774071 0.89 S1PR1 (0.67) S1PR1S1PR3SMN1; SMN2TP53NFKB1
SCHEMBL2809498 0.87 S1PR1 (0.70) S1PR1S1PR3SMN1; SMN2RARARARB
SCHEMBL2772009 0.86 S1PR1 (0.52) S1PR1S1PR3SMN1; SMN2TP53NFKB1
SCHEMBL2809248 0.85 S1PR1 (0.66) S1PR1S1PR3SMN1; SMN2RARARARB
SCHEMBL2807738 0.83 S1PR1 (0.71) S1PR1S1PR3RARARARBRARG
SCHEMBL2772255 0.82 S1PR1 (0.64) S1PR1S1PR3SMN1; SMN2TP53NFKB1
SCHEMBL2772693 0.81 S1PR1 (0.61) S1PR1S1PR3RARARARBRARG
SCHEMBL2803531 0.81 S1PR1 (0.59) S1PR1S1PR3RARARARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193125-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-01-11 EP disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 S1PR1 483/4885S1PR3 335/4885SMN1; SMN2 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.